Overview

• Cidara will present translational CD388 data linking mouse influenza models to Phase 2b prevention findings on October 23 at ESWI in Valencia, Spain.
• JP Morgan initiated coverage with an Overweight rating and a $200 price target, highlighting growing investor interest.
• Cidara shares rose about 3% to $114.10 during Friday’s regular session, according to Benzinga Pro.
• The FDA granted Breakthrough Therapy designation to CD388 on Thursday, following its 2023 Fast Track designation.
• CD388 progressed from positive Phase 2b NAVIGATE results in June to the Phase 3 ANCHOR trial launch in September, leveraging Cidara’s Cloudbreak drug–Fc conjugate platform for single-dose influenza prevention.